Outsourcing Highly Potent API – It's Both What You Know And Who You Know

Advances in clinical pharmacology and oncology research have increased the demand for highly potent active pharmaceutical ingredients (HPAPI). New therapies, such as antibody-drug conjugates (ADCs), can better target cancerous tumors with less collateral damage to healthy cells while APIs used in medicines that treat other disease areas are becoming more potent and targeted. This is unquestionably good news for patients, many of whom can expect to suffer fewer side effects from the medications of the future. However, there is a challenge for drug makers who may want to begin producing higher potency APIs but have built their manufacturing systems around broad-spectrum medications that don’t use HPAPI or require high-containment facilities.